Effects of platelets derived growth factors on fresh and frozen embryo process during IVF
Not Applicable
- Conditions
- Health Condition 1: O268- Other specified pregnancy relatedconditions
- Registration Number
- CTRI/2019/10/021788
- Lead Sponsor
- Seragen Biotherapeutics private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Thin endometrium, Two failed implantation in previous IVF cycles
Exclusion Criteria
Patient on hormone therapy, Diagnosis of cancer or Chemotherapy treatments,Abnormal platelet function, Previous Incision in the uterus,
Endocrine abnormalities such as hyperprolactinemia or abnormal thyroid functions, Systemic use of corticosteroids two weeks before the procedure,Serious, pre-existing medical conditions such as bleeding disorders, septicemia, TB, Acute and chronic infections,Severe metabolic and systemic disorders,Chronic Liver Pathology,Anti-coagulation therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in thickness of endometrium along with improved blood supply to endometrium; increase in endometrial receptivityTimepoint: First dose will be administered on the 5-6th day of menstrual cycle and the second dose will be administered 5 days after the first dose and third dose will be administered 48 hours/2 days before embryo transfer. The endometrium lining will be recorded before each dose.
- Secondary Outcome Measures
Name Time Method To determine clinical pregnancy rateTimepoint: 2 year